Insulin degludec - Biologic Drug Details

Summary for insulin degludec

Tradenames:	1
High Confidence Patents:	9
Applicants:	1
BLAs:	3
Suppliers: see list	3
Recent Clinical Trials:	See clinical trials for insulin degludec
Drug Prices:	Drug price information for insulin degludec

Recent Clinical Trials for insulin degludec

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Yanbing Li	PHASE4
Dasman Diabetes Institute	PHASE4
Profil Institut fr Stoffwechselforschung GmbH	PHASE1

See all insulin degludec clinical trials

Pharmacology for insulin degludec

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin degludec Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin degludec Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,039,816	2035-04-30	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,213,485	2035-08-27	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,213,546	2036-03-08	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,220,155	2026-07-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,307,431	2037-11-15	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,357,616	2037-11-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin degludec Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,137,172	2034-04-30	Patent claims search
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,335,464	2038-06-27	Patent claims search
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,369,114	2037-05-24	Patent claims search
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,493,125	2036-12-05	Patent claims search
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,610,595	2037-10-13	Patent claims search
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	10,639,308	2038-11-02	Patent claims search

International Patents for insulin degludec

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015168380
Canada	2958342
China	106714823
Denmark	3192524
European Patent Office	3192524
Spain	2907125

Supplementary Protection Certificates for insulin degludec

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1390036-0	Sweden		PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
C20130014 00133	Estonia		PRODUCT NAME: DEGLUDEKINSULIIN/ASPARTINSULIIN;REG NO/DATE: K(2013)368 (LOPLIK) 23.01.2013
138 5015-2013	Slovakia		PRODUCT NAME: INZULIN DEGLUDEK; REGISTRATION NO/DATE: EU/1/12/807/001 - EU/1/12/807/015 20130121
92213	Luxembourg		PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE
C300596	Netherlands		PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001EU/1/12/807/004EU/1/12/807/005EU/1/12/807/007EU/1/12/807/008EU/1/12/807/009EU/1/12/807/012EU/1/12/807/013EU/1/12/807/015 2013210121
C201300035	Spain		PRODUCT NAME: INSULINA DEGLUDEC; NATIONAL AUTHORISATION NUMBER: EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF AUTHORISATION: 20130121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF FIRST AUTHORISATION IN EEA: 20130121

Insulin Degludec Market Dynamics and Financial Trajectory: Volumes, Pricing, Competitive Shifts, and Exclusivity Timeline

Last updated: July 12, 2026

Insulin degludec (marketed as Tresiba in the US; multiple brand names internationally) has maintained sustained growth driven by long-acting, once-daily dosing and competitive switching from glargine-based regimens. The next phase is shaped by (1) biosimilar uptake risk, (2) payer formulary tightening and contracting, and (3) product lifecycle moves such as combination pens and concentration/volume optimization. Financial outcomes over the next 3 to 7 years depend on biosimilar entry timing by geography and contract structure rather than on demand deterioration.

---

What is the market size and revenue trajectory for insulin degludec?

Featured snippet: Insulin degludec revenue growth has tracked global basal insulin expansion and share gains in markets where dosing convenience supports formulary positioning, with upside concentrated in high-coverage geographies and downside driven by biosimilar pricing pressure and clawback-driven net price erosion.

Global demand drivers

• Basal insulin volume growth: Longer-term diabetes incidence and improved persistence on basal regimens support steady volume trends.
• Clinical positioning: Degludec’s flatter pharmacodynamic profile and lower within-subject variability have supported prescriber adoption in guideline-concordant basal therapy.
• Device and adherence economics: Once-daily administration and pen usability tend to reduce missed doses and support payers’ preference for stable basal regimens.

Revenue decomposition used by investors

For insulin brands, revenue trajectory is typically explained by:

• Unit growth (patient starts and persistence, pen adoption)
• Net price (rebates, discounts, tender dynamics)
• Mix (U-100 vs higher concentrations where available; combo products)
• Geography (US vs EU vs emerging markets)
• Competitive headwinds (biosimilars of glargine and degludec, and cross-class substitution)

---

How do US payer policies and Medicare Part D pricing dynamics affect insulin degludec net sales?

Featured snippet: In the US, net sales for degludec are most sensitive to rebates and contract terms rather than list price, with insulin affordability programs and formulary management influencing net price realization.

Net price pressures that specifically matter

• Formulary tiering and prior authorization: Payers increasingly manage basal insulin through step edits and “preferred insulin” contracting.
• Insulin affordability initiatives: These programs reduce patient cost-sharing but do not eliminate payer rebates and can shift payer selection toward contracted lower-cost options.
• PBM rebate dynamics: Category-level competitive bidding and pharmacy channel leverage can compress net prices.
• State and federal pricing mandates: In some markets, insulin pricing oversight influences contracting cadence and discount structures.

What to monitor in quarterly prints

• Net sales vs volume divergence: If unit growth continues while net sales flatline, pricing and rebates are dominating.
• Channel inventory and buy-in timing: Large wholesalers or distributors can create quarter-to-quarter swings, particularly during formulary transitions.
• Mix shift: Any shift from lower concentration to higher concentration products can change realized revenue per unit.

---

How strong is the biosimilar threat to insulin degludec, and when is risk highest?

Featured snippet: The dominant financial risk is biosimilar entry timing and subsequent share loss, with the largest post-entry impact in geographies where tendering and formulary switching are aggressive.

Key economic mechanism

Biosimilar risk typically follows:

1. Launch-year pricing compression (rebates and contracting revise preferred status)
2. Formulary re-tiering (prior authorization eases for biosimilars)
3. Persistence drag (patients switch over prescription renewals)
4. Long-run stabilization at a lower net price floor

Risk indicators

• Pipeline activity: Biosimilar applicants and manufacturing readiness signal the probability of near-term launches.
• Tender results: Public and private tenders that include degludec biosimilars show the pace of contracting.
• GPO and PBM formulary changes: These often precede measurable share loss.

What this means for the financial trajectory

• Base case: Gradual share erosion after launch, not an immediate collapse, because basal insulin switching can be slow and can require titration.
• Downside case: Rapid preference shift under tender-like contracts and aggressive step edits, leading to steep net price compression.

---

When does insulin degludec lose exclusivity by product and geography?

Featured snippet: Exclusivity timing determines the step-function risk window for biosimilar launches, with different layers expiring on different schedules (regulatory exclusivity, patent estate, and data protection across regions).

US framework that governs timing

• Biologics exclusivity (BLA exclusivity periods)
• Patent estate (composition, formulation, device, and method-of-use)
• Hatch-Waxman/Biologics license equivalents: Biosimilar pathways can hinge on patent challenges and final court outcomes.

EU and other markets

• Data and market exclusivity rules differ by member state and marketing authorization history.
• Patent enforcement tends to be country-specific, so launch risk can be staggered rather than synchronized.

---

What patents protect insulin degludec, and how do they map to competitive entry barriers?

Featured snippet: Patent estates in insulin biologics commonly include composition of matter, formulation/physicochemical stability, device/administration features, and manufacturing/process elements; these create entry barriers even after regulatory acceptance.

Barrier types that delay biosimilar meaningful entry

• Composition and engineered stability claims: Block true “same molecule” equivalents in specific claim scopes.
• Formulation and concentration claims: Can delay certain presentations even if the core molecule is approved.
• Device and needle/presentation claims: Pen formats can be a gating factor for substitution.
• Manufacturing process claims: Even with an approved biosimilar, process-adherent manufacturing constraints can restrict supply or delay technical comparability.

Litigation pattern that shapes market behavior

• Injunction risk: Even limited injunction coverage can delay uptake.
• Settlement agreements: Often trade off launch dates for non-material licensing terms, shaping the observed entry curve.

---

How does insulin degludec compare with insulin glargine (and glargine biosimilars) in market dynamics?

Featured snippet: Degludec and glargine compete inside basal insulin budgets; where glargine biosimilars have established share, they can cap upside for degludec unless degludec is positioned as a preferred alternative for specific patient segments.

Competitive substitution logic

• Payer preference can override prescriber preferences when biosimilars become the lowest contracted cost.
• Patient segmentation influences switching speed:
  • Hypoglycemia risk profiles can drive degludec retention in certain cohorts
  • Adherence patterns can drive continued use of pen-based basal delivery

Net sales implication

• If glargine biosimilar penetration increases, degludec share gains slow unless net pricing is also competitive.

---

What formulation and delivery products drive insulin degludec mix, and how does mix affect profitability?

Featured snippet: Product mix changes can move margin even when volumes are steady because net price and rebate intensity differ by concentration, device, and combination formulations.

Mix levers

• U-100 vs higher concentration presentations (where available): can shift revenue per pen and distribution economics.
• Combination products: can improve retention and reduce payer friction through “single formulary pathway” management.
• Pen ecosystem: Pen count, cartridge interchange compatibility, and training support can influence churn.

Profitability impact channels

• Cost of goods sold depends on fill-finish and supply chain scaling.
• Commercial expense rises during switching events but can fall once formulary positioning stabilizes.
• Revenue recognition timing can differ by packaging format and distribution terms.

---

What generic entry risks exist for insulin degludec?

Featured snippet: True generics do not apply to insulin biologics in the same way as small molecules; the practical “generic” risk is biosimilar substitution and interchangeability, not copycat chemical generics.

Substitution risk pathways

• Biosimilar approvals: Regulatory authorization can increase competition even without interchangeability determinations.
• Interchangeability (where applicable): When recognized, pharmacy-level switching can accelerate share loss.
• Substitution policy constraints: States and PBMs can allow or restrict substitution based on product designation.

---

How do insulin degludec settlements and FDA regulatory milestones influence launch timing and sales ramps?

Featured snippet: Settlement timing and FDA review milestones can shift the launch window by months to years, changing whether biosimilar uptake occurs before or after major formulary renewal cycles.

What affects the sales ramp shape

• Regulatory acceptance: Approval timelines influence when new SKUs can enter distribution channels.
• Court/settlement resolution: Resolves whether biosimilars can launch immediately or later.
• Contracting cadence: Payers often change preferred status at renewal milestones.

Impact on financial trajectory

• Early entrants often secure deeper formulary placement and higher share before incumbents respond.
• Late entrants can still win share but often with reduced net price upside and higher rebate requirements.

---

What is the competitive landscape for insulin degludec in basal insulin, and how does it affect revenue share?

Featured snippet: Revenue share is driven by contracting outcomes against other basal insulins, including glargine biosimilars, detemir in some markets, and other long-acting options depending on local availability.

Competitor set (category-level)

• Long-acting basal insulins: glargine (including biosimilars where available), detemir (where still present), and other long-acting analogs
• Biosimilar basals: price competition often comes through biosimilar glargine as much as through degludec biosimilar entry
• Fixed-ratio combination products: can shift patients toward different budget lines

Competitive share logic

• If payers can standardize basal coverage using cheaper biosimilars, degludec share growth typically slows.
• If degludec is contracted as “preferred” for specific cohorts, it can keep share even under biosimilar price pressure.

---

How does insulin degludec pricing and contract structure determine downside in a biosimilar launch scenario?

Featured snippet: The magnitude of sales erosion depends on net price drop and how quickly the brand loses preferred placement; volume switching is slower than price switching.

Scenario framework investors use

• Mild competition:
  • Limited formulary displacement
  • Modest net price reduction
  • Volume decline is gradual
• Moderate competition:
  • Preferred status changes in select plans
  • Higher rebate intensity on incumbents
  • Volume decline accelerates
• Severe competition:
  • Broad tender-like preferred placement for biosimilars
  • Steep net price compression
  • Volume loss becomes structural

What to observe in financial statements

• Operating margins tracking alongside net sales: if rebates rise, margins compress even if units hold.
• “Other revenue” and chargebacks: can spike in launch quarters due to contracting resets.

---

How do manufacturing scale, supply continuity, and device procurement affect insulin degludec market share?

Featured snippet: Supply reliability and pen availability can determine whether the brand retains accounts during competitive shifts; stockouts can accelerate churn even when clinical preference remains.

Supply chain and operational risk factors

• Fill-finish capacity constraints can limit ability to meet tender volumes.
• Pen device procurement delays can slow distribution and drive substitutions to contracted alternatives.
• Global logistics and regulatory batch release timing can create temporary availability gaps.

---

Key timelines to model for financial planning

Featured snippet: Model a step change around biosimilar entry windows and formulary renewal cycles, not just around regulatory approval dates.

Timeline model (generic structure)

• Pre-entry (12 to 24 months): contracting watch, payer readiness, patent litigation milestones
• Launch window (0 to 6 months after biosimilar authorization/launch): net price resets, preferred status shifts, rebate adjustments
• Stabilization (6 to 24 months): share stabilizes; pricing plateaus, new cohort switching continues

---

Key Takeaways

• Insulin degludec’s financial trajectory is driven by the interaction of basal insulin volume growth, US net price mechanisms (rebates, PBM contracting, tiering), and competitive contracting against glargine biosimilars and future degludec biosimilars.
• The main downside lever is biosimilar entry and interchangeability dynamics by geography, which can compress net price and shift preferred status quickly through tenders and formulary renewals.
• Profitability is highly sensitive to mix across concentrations, pen formats, and combination offerings, with margin impacted by rebate intensity and supply chain scale.
• Sales erosion after biosimilar entry typically starts with net price before volumes, so monitoring unit pricing and share changes in tandem is critical for quarterly forecasting.

---

FAQs

1. Do biosimilars of insulin degludec usually cause immediate patient switching, or does it happen gradually?
2. How do PBM formulary renewals change insulin degludec net price faster than unit volume?
3. Which degludec presentation formats (pens/concentrations/combos) typically hold share best after biosimilar entry?
4. How does competition from glargine biosimilars influence degludec demand in payer-covered populations?
5. What operational factors most often disrupt insulin degludec continuity of supply during high switching periods?

---

References (APA)

1. FDA. (n.d.). BLA and biosimilar-related information and approval pathways. US Food and Drug Administration. https://www.fda.gov
2. FDA. (n.d.). Purple Book: Data sources on biological products. US Food and Drug Administration. https://www.fda.gov
3. Orange Book. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
4. Global regulatory and market framework documents on biologics exclusivity and biosimilar approval concepts. US and EU regulatory authorities.